[Results of treatment with rifampicin in 39 patients hospitalized in our service during 1970-1971-1972]. 1974

M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah

UI MeSH Term Description Entries
D008297 Male Males
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
February 1973, Wisconsin medical journal,
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
January 1973, Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
September 1972, Srpski arhiv za celokupno lekarstvo,
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
January 1985, Folia haematologica (Leipzig, Germany : 1928),
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
September 1972, Lyon medical,
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
January 1972, Atti della Accademia medica lombarda,
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
March 1973, Wiadomosci lekarskie (Warsaw, Poland : 1960),
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
January 1974, Nordisk veterinaermedicin,
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
January 1977, Revista de sanidad e higiene publica,
M Maalej, and A Chabbou, and M Zbiba, and B El Gharbi, and S Halfon, and T El Gharbi, and M Cheniti, and L El Mekki, and F Djen Ayah, and M L Chebbi, and M Jeguirim, and M Ben Salah
January 1974, Materia medica Polona. Polish journal of medicine and pharmacy,
Copied contents to your clipboard!